Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ)

31,49 +0,14 (+0,45%) Alla chiusura: 03:04PM CST

Shenzhen Salubris Pharmaceuticals Co., Ltd.

NEO Building No. 6009, Tower B
37th Floor Shennan Road Futian District
Shenzhen 518040
China
86 755 8386 7888
https://www.salubris.com

Settore/i: Healthcare
Settore: Medical Instruments & Supplies
Impiegati a tempo pieno: 3.517

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Jie Yan	GM & Director	N/D	N/D	1972
Ms. Yun Kong	CFO & Financial Manager	N/D	N/D	1973
Mr. Ping Chen	Deputy General Manager	N/D	N/D	1970
Mr. Jianfeng Yang	Secretary of the Board of Directors & Non Independent Director	N/D	N/D	1975
Ms. Song Ping Zhao	Deputy General Manager	N/D	N/D	1970
Dr. Xie Heng M.D., Ph.D.	Chief Medical Officer	N/D	N/D	N/D

Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CNY.

Descrizione

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also provides interventional medical devices for therapy of cardiovascular and cerebrovascular diseases, peripheral blood vessels, structural heart diseases, electrophysiology, and cardiac rhythm management. In addition, the company develops Sacubitril Allisartan Calcium, Allisartan Isoproxil Amlodipine Besylate Tablets, and Allisartan IsoproxilIndapamide Sustained-release Tablets, which are in phase III clinical trial for treatment of hypertension; Enarodustat, a drug for renal anemia; SAL056 medicine used for treating osteoporosis; and Fotagliptin and SAL015 for diabetes which are under phase III clinical trial. Further, it develops Sacubitril Allisartan Calcium and SAL007 medicine for chronic heart failure; SAL003 medicine that is in phase I clinical trial to treat hypercholesterolemia; and SAL0114 for depressant indications. Additionally, the company's preclinical products are SAL023 for osteoporosis; SAL0112 to treat diabetes; and SAL008 for the treatment of tumors. Furthermore, it develops medical devices, such as intracranial segment of vertebral artery stent, which is under clinical trials for Neurology intervention; SaExtenVena cava filter and Microneedle perfusion absolute ethanol delivery system used for Peripheral vascular intervention; and LAMax LAAC Left Atrial Appendage Occluder that is in clinical trials used for Structural heart disease. The company was founded in 1998 and is headquartered in Shenzhen, China. Shenzhen Salubris Pharmaceuticals Co., Ltd. is an operating subsidiary of Salubris Pharmaceuticals Co., Ltd.

Governance aziendale

L'ISS Governance QualityScore di Shenzhen Salubris Pharmaceuticals Co., Ltd. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.